GETUG-AFU V05 VESPER 试验中尿路上皮癌变异组织学或 divergent differentiation 对患者结局的影响
这项 VESPER 试验事后研究纳入 300 例接受新辅助化疗的肌层浸润性膀胱癌患者,评估变异组织学或 divergent differentiation(VH/DD)与病理缓解和无进展生存(PFS)的关系。VH/DD 见于 177/300(59%)例,总体与完全病理缓解、降期及 PFS 无显著关联;但嵌套亚型与完全病理缓解和降期几率降低相关,≥50% 鳞状分化或微乳头亚型与 PFS 风险升高相关。
要点
- VH/DD 见于 177/300(59%)例,其中 85/177 例为 predominante(≥50%)。
- VH/DD(≥10% 或 ≥50%)与完全病理缓解、降期及 PFS 无显著关联。
- ≥50% 鳞状分化或微乳头亚型与 PFS 风险升高相关。
核心结论
- 在 VESPER 试验中,未观察到 VH/DD 与新辅助化疗后结局相关的证据,但 predominant 鳞状分化或微乳头亚型的特定存在可能与较短 PFS 相关。
研究设计与样本
- VESPER 临床试验的事后研究,纳入 300 例接受新辅助化疗且经尿道诊断切片可用的患者,回顾 VH/DD 的存在及百分比,病理缓解采用 logistic 回归、PFS 采用 Cox 比例风险回归,所有模型均校正随机分组臂。
主要发现
- VH/DD 见于 177/300(59%)例,其中 predominant(≥50%)者为 85/177 例。
- 与纯 UC 相比,VH/DD(≥10% 或 ≥50%)与完全病理缓解(ypT0N0;校正 OR 0.79,95%CI 0.49-1.29)、降期(≤ypT1N0;校正 OR 0.62,95%CI 0.37-1.02)及 PFS 风险升高(校正 HR 1.24,95%CI 0.83-1.85)均无显著关联。
- 与纯 UC 相比,嵌套亚型与完全病理缓解几率降低(校正 OR 0.33,95%CI 0.12-0.88)和降期几率降低(校正 OR 0.30,95%CI 0.13-0.74)相关。
- 与纯 UC 相比,≥50% 鳞状分化的 UC 观察到 PFS 风险升高(校正 HR 2.11,95%CI 1.01-4.38),微乳头亚型观察到 PFS 风险升高(校正 HR 2.03,95%CI 0.98-4.22)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Variant histology or divergent differentiation (VH/DD) of urothelial carcinoma (UC) may impact outcomes after neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer. Our aim was to assess the pathological response and progression-free survival (PFS) of patients with VH/DD in the prospective VESPER clinical trial. MATERIALS AND METHODS: This post hoc study included 300 NAC-treated patients with available transurethral diagnostic slides. Presence and percentage of VH/DDs were reviewed. For pathological response, logistic regression models were computed to measure association with VH/DD. For PFS, the associations were estimated in Cox proportional hazard regression model. All models were adjusted for randomization arm. RESULTS: VH/DD was identified in 177/300 patients (59%) and was predominant (≥50%) in 85/177. Compared to pure UC, VH/DD (≥10% or ≥50%) was not associated with a difference in proportion of complete pathological response (ypT0N0; OR adjusted: 0.79, 95% CI 0.49-1.29), downstaging (≤ypT1N0; OR adjusted: 0.62, 95% CI 0.37-1.02), or with an increased hazard of PFS (HR adjusted: 1.24, 95% CI 0.83-1.85). However, comparing specific VH/DD to pure UC, nested subtype was associated with decreased odds of complete pathological response (OR adjusted: 0.33, 95% CI 0.12-0.88) and downstaging (OR adjusted: 0.30, 95% CI 0.13-0.74), and an increased hazard of PFS was observed for UC with ≥ 50% squamous differentiation (HR adjusted: 2.11, 95% CI 1.01-4.38) or micropapillary subtype (HR adjusted: 2.03, 95% CI 0.98-4.22). CONCLUSIONS: In the VESPER trial, we did not observe evidence for association of VH/DD with outcomes after NAC, but the specific presence of a predominant squamous differentiation or micropapillary subtype may be associated with shorter PFS.
引用
- Allory Y, Culine S, Krucker C, et al. Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. J Urol. 2023. PMID: 38153961. doi:10.1097/JU.0000000000003836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。